Merck’s Leader in Oral PCSK9 Inhibitor Race Reduces Cholesterol in Pair of Phase 3 Trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlici...





